Rebound Psychiatric and Physical Symptoms After Gabapentin Discontinuation

Corá-Locatelli, Gabriela; Greenberg, Benjamin D.; Martin, Juliet; Murphy, Dennis L.

doi:10.4088/jcp.v59n0308a

Cited by 24 publications

(15 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All patients demonstrated improvements in anxiety, obsessive-compulsive symptoms, sleep, and mood on the basis of clinical evaluations. However, patients experienced a rebound of psychiatric symptoms once gabapentin was discontinued (228).…”

Section: Gabapentinmentioning

confidence: 99%

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Ameringen¹,

Mancini²,

Patterson³

et al. 2008

Medical Psychiatry

View full text Add to dashboard Cite

Section: Gabapentinmentioning

confidence: 99%

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Ameringen¹,

Mancini²,

Patterson³

et al. 2008

Medical Psychiatry

View full text Add to dashboard Cite

“…Gabapentin has been investigated in three small open OCD studies; all reported some benefit from gabapentin augmentation of a selective serotonin reuptake inhibitor (SSRI) [Chouinard et al, 1998;Cora-Locatelli et al, 1998;Kahn, Katzman, and Richter, unpublished]. There have also been a number of studies suggesting clinical utility of this agent in other anxiety disorders including panic, posttraumatic stress disorder (PTSD), generalized anxiety disorder (GAD), and social phobia [Schaffer and Schaffer, 1997;Pollack et al, 1998;Pande et al, 1999Pande et al, , 2000Brannon et al, 2000].…”

Section: Introductionmentioning

confidence: 99%

Evidence for the gamma‐amino‐butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive‐compulsive disorder

Zai

Arnold

Burroughs

et al. 2005

American J of Med Genetics Pt B

View full text Add to dashboard Cite

Obsessive-compulsive disorder (OCD) is a well-recognized severe neuropsychiatric illness. Genetic factors are believed to be important etiologically. Although historically genetic testing has focused on the serotonergic and dopaminergic systems, there is increasing evidence that the major inhibitory neurotransmitter, gamma-aminobutyric acid (GABA), may also be functionally involved. Furthermore the GABA type B receptor 1 (GABBR1) gene has been localized to chromosome 6p21.3 region, which has shown linkage to OCD. We investigated five polymorphisms (A-7265G substitution; C10497G substitution; A33795G substitution in the 3'-UTR; Ser-491-Ser-T1473C transition; Phe-659-Phe-T1977C transition) in the GABBR1 gene in a sample of 159 DSM-IV OCD probands and their families, using the transmission disequilibrium test (TDT). A trend was observed with an over-transmission of -7265A allele at the A-7265G polymorphism and OCD (chi2 = 3.270, P = 0.071). Moreover, the TDT haplotype analysis using TRANSMIT showed a trend toward association with the haplotype of the five polymorphisms together [2.1.1.2.1 (A-7265G.C10497G.Ser-491-Ser.Phe-659-Phe.A33795G)] with a Chi-square value of 3.418, which corresponds to a P-value of 0.065 (overall chi2 = 6.353, 5 df, P = 0.273). Moreover, a trend was observed for the total Yale-Brown obsessive-compulsive scale score in the A-7265G polymorphism (-7265A: z = 1.934, P = 0.053) using the Family-Based Association Test, considering the diagnosis of OCD and then the clinically relevant quantitative phenotypes. The observed trends suggest that further investigations of the role of the GABBR1 gene in OCD are warranted.

show abstract

“…In contrast, rebound anxiety-related symptoms (anxiety, depression, decreased sleep) developed in five patients with OCD after beginning adjunctive gabapentin therapy. 22 All five patients reported the symptoms to be more severe than before the drug was added to their regimen. Gabapentin was restarted in four of the patients with resolution of the symptoms within a week.…”

Section: Anxiety Disordersmentioning

confidence: 93%

“…21 The drug was successful in the treatment of alcohol withdrawal in six patients. 24 In the initial assessment with the revised Clinical Institute Withdrawal for Alcohol scale (CIWA-R), the subjects' average initial score was 17 (range [10][11][12][13][14][15][16][17][18][19][20][21][22][23][24][25][26][27], with a score of 10 considered moderate withdrawal. The dosage of gabapentin was 400 mg 3 times/day for 3 days, twice/day for 2 days, and then once/day for 1 day.…”

Section: Substance Use Disordersmentioning

confidence: 99%

Gabapentin: A Review of Published Experience in the Treatment of Bipolar Disorder and Other Psychiatric Conditions

Letterman

Markowitz

1999

Pharmacotherapy

View full text Add to dashboard Cite

Successful therapy with valproate and carbamazepine in patients with psychiatric disorders led to investigation of other anticonvulsants for similar indications. Gabapentin is a relatively new anticonvulsant being investigated for potential use in the treatment of bipolar disorder (BD), anxiety disorders, behavioral dyscontrol, and substance use disorders. Its favorable side effect profile, absence of the need for therapeutic drug monitoring, and minimal drug interactions give gabapentin a potential role in these indications. Computer searches of the biomedical literature were undertaken to identify all pertinent case reports, case series, and studies of the drug as monotherapy or adjunctive therapy for BD; 10 reports were retrieved. In the treatment of various anxiety disorders, one study, one case report, and one case series were identified. At least one case series described gabapentin therapy for alcohol withdrawal and one case report of the drug for agitation associated with dementia. Published, well-designed studies evaluating the agent's effectiveness as monotherapy for BD are lacking. Its benefit as an adjunctive treatment with other mood stabilizers is also unestablished. Data regarding its efficacy in the treatment of anxiety disorders or manifestations of substance abuse are limited. These areas may deserve further investigation.

show abstract

Rebound Psychiatric and Physical Symptoms After Gabapentin Discontinuation

Cited by 24 publications

References 1 publication

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Antiepileptic Drugs in the Treatment of Anxiety Disorders: Role in Therapy

Evidence for the gamma‐amino‐butyric acid type B receptor 1 (GABBR1) gene as a susceptibility factor in obsessive‐compulsive disorder

Gabapentin: A Review of Published Experience in the Treatment of Bipolar Disorder and Other Psychiatric Conditions

Contact Info

Product

Resources

About